A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refract
Disease Name
Systemic Lupus Erythematosus (SLE) with Lupus Nephritis (LN)